• mail us help@24marketresearch.com
  • Int'l 1(332) 2424 294 (Int'l)

TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Europe Tranexamic Acid Market, Outlook and Forecast 2025-2030

Europe Tranexamic Acid Market, Outlook and Forecast 2025-2030

  • Category:Chemicals and Materials
  • Published on : 08 January 2025
  • Pages :205
  • Formats:
  • Report Code:24MRES-8026566
Click for best price

Best Price: $2600

The Europe Tranexamic Acid market was valued at US$ 245.6 million in 2024 and is projected to reach US$ 345.4 million by 2030, at a CAGR of 5.8%
Tranexamic Acid is a synthetic amino acid derivative used as an antifibrinolytic medication. This pharmaceutical compound effectively controls bleeding in various clinical settings. Modern formulations include various delivery systems and improved stability profiles.
Healthcare leads with 55% market share, followed by pharmaceuticals (30%) and research (8%). Germany leads with 35% share. Clinical applications expanded 42% since 2022. R&D reached

TABLE OF CONTENTS

1 Market Overview    



1.1 Product Overview and Scope of Tranexamic Acid 



1.2 Segment by Type    



1.2.1 Europe Market Size YoY Growth Rate Analysis by Type: 2023 VS 2030    

1.2.2 USP25    

1.2.3 BP2000

1.2.4 Other


1.3 Segment by Application  



1.3.1 Europe Market Size YoY Growth Rate Analysis by Application: 2023 VS 2030    

1.3.2    Trauma

1.3.3    Craniocerebral Trauma

1.3.4    Menorrhagia

1.3.5    Postpartum Hemorrhage

1.3.6    Surgery

1.3.7    Other Treatment

1.3.8    Whitening Cosmetics

1.4 Europe Market Growth Prospects    

1.4.1 Europe Revenue Estimates and Forecasts (2019-2030)    

1.4.2 Europe Production Estimates and Forecasts (2019-2030)  



2 Europe Growth Trends    



2.1 Industry Trends    

2.1.1 SWOT Analysis    

2.1.2 PESTEL Analysis    

2.1.3 Porter’s Five Forces Analysis    

2.2 Potential Market and Growth Potential Analysis    



3 Market Competition by Manufacturers  



3.1 Europe Production by Manufacturers (2019-2023)    

3.2 Europe Revenue Market Share by Manufacturers (2019-2023)    

3.3 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)    

3.4 Europe Average Price by Manufacturers (2019-2023)    

3.5 Manufacturers Production Sites, Area Served, Product Type    

3.6 Market Competitive Situation and Trends    

3.6.1 Market Concentration Rate    

3.6.2 Europe 5 and 10 Largest Players Market Share by Revenue    

3.6.3 Mergers & Acquisitions, Expansion  



4 Production by Region



4.1 Europe Production    

4.1.1 Europe Production YoY Growth Rate (2019-2023)    

4.1.2 Europe Production, Revenue, Price and Gross Margin (2019-2024)  



5 Consumption by Region  



5.1 Europe    

5.1.1 Europe Consumption by Country    

5.1.2 Europe Sales, Consumption, Export, Import (2019-2023)    

5.1.1 Germany    

5.2.2 United Kingdom

5.3.3 France

5.4.4 Italy

5.5.5 Spain

5.6.6 Netherlands

5.7.7 Belgium


6 Segment by Type   



6.1 Europe Production Market Share by Type (2019-2024)    

6.2 Europe Revenue Market Share by Type (2019-2024)    

6.3 Europe Price by Type (2019-2024) 



7 Segment by Application  



7.1 Europe Production Market Share by Application (2019-2024)    

7.2 Europe Revenue Market Share by Application (2019-2024)    

7.3 Europe Price by Application (2019-2024)  



8 Key Companies Profiled    



8.1 Sanofi    

8.1.1 Sanofi Corporation Information    

8.1.2 Sanofi Product Portfolio    

8.1.3 Sanofi Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.1.4 Sanofi Main Business and Markets Served    

8.1.5 Sanofi Recent Developments/Updates    

8.2 Pfizer Inc.    

8.2.1 Pfizer Inc. Corporation Information    

8.2.2 Pfizer Inc. Product Portfolio    

8.2.3 Pfizer Inc. Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.2.4 Pfizer Inc. Main Business and Markets Served    

8.2.5 Pfizer Inc. Recent Developments/Updates    

8.3 Bayer AG    

8.3.1 Bayer AG Corporation Information    

8.3.2 Bayer AG Product Portfolio    

8.3.3 Bayer AG Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.3.4 Bayer AG Main Business and Markets Served    

8.3.5 Bayer AG Recent Developments/Updates    

8.4 CSL Behring    

8.4.1 CSL Behring Corporation Information    

8.4.2 CSL Behring Product Portfolio    

8.4.3 CSL Behring Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.4.4 CSL Behring Main Business and Markets Served    

8.4.5 CSL Behring Recent Developments/Updates    

8.5 Ferring Pharmaceuticals    

8.5.1 Ferring Pharmaceuticals Corporation Information    

8.5.2 Ferring Pharmaceuticals Product Portfolio    

8.5.3 Ferring Pharmaceuticals Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.5.4 Ferring Pharmaceuticals Main Business and Markets Served    

8.5.5 Ferring Pharmaceuticals Recent Developments/Updates    

8.6 Octapharma    

8.6.1 Octapharma Corporation Information    

8.6.2 Octapharma Product Portfolio    

8.6.3 Octapharma Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.6.4 Octapharma Main Business and Markets Served    

8.6.5 Octapharma Recent Developments/Updates    

8.7 Sobi - Swedish Orphan Biovitrum    

8.7.1 Sobi - Swedish Orphan Biovitrum Corporation Information    

8.7.2 Sobi - Swedish Orphan Biovitrum Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.7.3 Sobi - Swedish Orphan Biovitrum Main Business and Markets Served    

8.7.4 Sobi - Swedish Orphan Biovitrum Recent Developments/Updates    

8.8 Grifols SA    

8.8.1 Grifols SA Corporation Information    

8.8.2 Grifols SA Product Portfolio    

8.8.3 Grifols SA Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.8.4 Grifols SA Main Business and Markets Served    

8.8.5 Grifols SA Recent Developments/Updates    

8.9 Takeda Pharmaceutical Company    

8.9.1 Takeda Pharmaceutical Company Corporation Information    

8.9.2 Takeda Pharmaceutical Company Product Portfolio    

8.9.3 Takeda Pharmaceutical Company Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.9.4 Takeda Pharmaceutical Company Main Business and Markets Served    

8.9.5 Takeda Pharmaceutical Company Recent Developments/Updates    

8.10 LFB Group    

8.10.1 LFB Group Corporation Information    

8.10.2 LFB Group Product Portfolio    

8.10.3 LFB Group Production Capacity, Revenue, Price and Gross Margin (2019-2024)    

8.10.4 LFB Group Main Business and Markets Served    

8.10.5 LFB Group Recent Developments/Updates    


9 Manufacturing Cost Analysis    



9.1 Key Raw Materials Analysis    

9.1.1 Key Raw Materials    

9.1.2 Key Suppliers of Raw Materials    

9.2 Proportion of Manufacturing Cost Structure    

9.3 Manufacturing Process Analysis of Tranexamic Acid    

9.4 Industrial Chain Analysis    



10 Marketing Channel, Distributors and Customers  



 10.1 Marketing Channel    

10.2 Distributors List    

10.3 Customers    



11 Market Dynamics



11.1 Industry Trends    

11.2 Market Drivers    

11.3 Market Challenges    

11.4 Market Restraints    



12 Production and Supply Forecast



12.1 Europe Production, Revenue Forecast (2024-2030)    



13 Consumption and Demand Forecast  



 13.1 Europe Forecasted Consumption of by Country    



14 Forecast by Type and by Application  



14.1 Europe Production, Revenue and Price Forecast by Type (2024-2030)    

14.1.1 Europe Forecasted Production of by Type (2024-2030)    

14.1.2 Europe Forecasted Revenue of by Type (2024-2030)    

14.1.3 Europe Forecasted Price of by Type (2024-2030)    

14.2 Europe Production, Revenue and Price Forecast by Application (2024-2030)    

14.2.1 Europe Forecasted Production of by Application (2024-2030)    

14.2.2 Europe Forecasted Revenue of by Application (2024-2030)    

14.2.3 Europe Forecasted Price of by Application (2024-2030)  



15 Research Findings and Conclusion   



16 Methodology and Data Source    



16.1 Methodology/Research Approach    

16.1.1 Research Programs/Design    

16.1.2 Market Size Estimation    

16.1.3 Market Breakdown and Data Triangulation    

16.2 Data Source    

16.2.1 Secondary Sources    

16.2.2 Primary Sources    

16.3 Author List    

16.4 Disclaimer    



17 Appendix    



17.1 Note    

17.2 Examples of Clients    

LIST OF TABLES & FIGURES



SELECT A FORMAT

USD GBP EURO YEN Single User License
USD GBP EURO YEN Multi User License
USD GBP EURO YEN Corporate User License

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy
check discount